MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks
MaxCyte (NASDAQ: MXCT), a cell-engineering company, has reiterated its 2026 revenue guidance of $30-$32 million, driven by high-margin consumables and Strategic Platform License (SPL) milestones. The company recently secured a multi-platform technology license partnership with Genentech, boosting its credibility and potential for enterprise deals. Despite this positive development, MaxCyte continues to face challenges such as lumpy SPL revenue, ongoing operating losses, and high stock volatility.
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte has introduced CHANGE-seq-BE™ and ONE-seq-BE™ assays through its SeQure™ service to enhance off-target assessment for genome editing therapies, specifically for adenine and cytosine base editors. These new assays provide sensitive nomination of off-target sites, addressing a critical gap in genome editing characterization. By offering orthogonal methods, MaxCyte aims to help therapeutic developers confidently assess and mitigate off-target risks, aligning with evolving regulatory expectations.
MaxCyte launches base editor off-target nomination assays
MaxCyte Inc. (NASDAQ:MXCT) has introduced two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, for base editors through its SeQure service. These assays are designed to help therapeutic developers identify and prioritize off-target sites, aligning with regulatory guidance like that from the FDA on genome editing safety. The company aims to provide sensitive and orthogonal assessment capabilities to mitigate off-target risks in clinical development.
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte (NASDAQ: MXCT) has launched two new off-target nomination assays, CHANGE-seq-BE™ and ONE-seq-BE™, for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service. These assays aim to provide sensitive and unbiased biochemical assessment of off-target sites, with ONE-seq-BE uniquely offering visibility into population-specific genetic variants that could influence off-target activity. The company states that these tools will help therapeutic developers align with evolving regulatory expectations, including recent FDA guidance on genome safety, by building stronger data packages for clinical development.
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT
MaxCyte, Inc. (NASDAQ: MXCT) generated $33.03 million USD in revenue last year. Its top-performing segment, PA Revenue, contributed $11.89 million USD, a decrease from the $14.01 million USD in the previous year. The United States was the largest regional contributor, accounting for $21.08 million USD of the revenue.
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands
MaxCyte reported Q2 2026 total revenue of $7.3 million, a 15% decrease year-over-year, yet reaffirmed its full-year 2026 revenue guidance of $30 million to $32 million, anticipating low-single-digit growth in the second half. The company highlighted a new enterprise-level partnership with Genentech, which expands access to MaxCyte's ExPERT GTx platform and other technologies across multiple programs. MaxCyte ended the quarter with a strong cash position of $141.9 million and no debt, continuing to invest in organic growth and share repurchases.
MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness
MaxCyte (MXCT) stock slipped despite beating Q2 revenue expectations, with the market focusing on its high gross margins and cash balance. The company's future hinges on its cell engineering bets and royalty streams from partnerships, while core revenue remains soft. Investors are weighing the potential of royalties from collaborations like Vertex's CASGEVY against persistent core business weakness.
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech
MaxCyte reported Q2 2026 total revenue of $7.3 million, a 15% year-over-year decrease but exceeding expectations due to sequential growth in instrument allocations and processing assembly demand. The company reaffirmed its full-year revenue guidance of $30 million to $32 million, anticipating low single-digit growth in the second half of the year. A new multi-platform partnership with Genentech and a strong cash position of $141.9 million underpin its strategic focus and ongoing share repurchase program.
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech
MaxCyte (MXCT) reportó ingresos totales de $7.3 millones en el segundo trimestre de 2026, una disminución del 15% interanual, pero reafirmó sus proyecciones anuales de ingresos entre $30 y $32 millones. La empresa destacó una nueva alianza multiplataforma con Genentech, que abarca múltiples programas desde investigación hasta fabricación cGMP, y la adopción de su tecnología DTx. MaxCyte finalizó el trimestre con $141.9 millones en efectivo y sin deuda, priorizando el crecimiento orgánico y la recompra de acciones.
MaxCyte Reports Second Quarter 2026 Financial Results
MaxCyte, Inc. announced its second quarter 2026 financial results, reporting $7.3 million in total revenue and reiterating its full-year 2026 guidance of $30 million to $32 million. The company highlighted a new strategic technology license partnership with Genentech and noted a reduction in net loss compared to the previous year. MaxCyte also disclosed a share repurchase of approximately $5.5 million and ended the quarter with $141.9 million in cash, cash equivalents, and investments.
MaxCyte revenue down 15% to USD 7.3M in Q2 2026
MaxCyte, Inc. reported its Q2 2026 financial results, showing a 15% decrease in total revenue to $7.3 million compared to Q2 2025. Despite the revenue dip, the company exceeded expectations due to strong instrument placements and stable processing assembly sales, and significantly reduced its net loss. MaxCyte also signed its first multi-platform technology license partnership with Genentech and reiterated its full-year 2026 revenue guidance of $30 million to $32 million.
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the first quarter, acquiring an additional 1.206 million shares to own a total of 1.993 million shares, representing 1.86% of the company. Other institutional investors also built positions, with hedge funds collectively owning 68.81% of MaxCyte's outstanding stock. Analysts currently hold a consensus "Hold" rating for MaxCyte with a $5.00 price target, and the company recently reported a slightly better-than-expected loss per share while revenue was in line with estimates.
Price to sales forward of MaxCyte, Inc. – MUN:MYE0
This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.
MaxCyte Q2 Results: EPS beats estimates, revenue falls 14.5% YoY
MaxCyte Inc. reported Q2 2026 results, with EPS beating estimates at $(0.08) despite a 14.53% year-over-year revenue decrease to $7.271 million. The company narrowed its net loss by 33.33% and announced a new strategic partnership with Genentech. MaxCyte also reaffirmed its full-year 2026 revenue guidance of $30-32 million, maintaining stability in its outlook.
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
MaxCyte Inc. reported a 15% decrease in total revenue for Q2 2026, reaching $7.3 million, with core revenue down 21%. Despite this, the company exceeded expectations and highlighted significant growth in CASGEVY royalties and a new enterprise-level partnership with Genentech to diversify revenue streams. MaxCyte is pivoting its commercial strategy to engage large pharmaceutical companies at a portfolio level while maintaining its SPL model for biotech firms, aiming for low single-digit revenue growth in the latter half of 2026.
MaxCyte (NASDAQ:MXCT) Issues Earnings Results
MaxCyte (NASDAQ:MXCT) reported a slight beat on earnings with an adjusted loss of $0.08 per share against an expected $0.09 loss, and revenue of $6.5 million, largely meeting estimates. The company reaffirmed its 2026 revenue guidance of $30 million–$32 million, anticipating instrument placements to drive growth in the latter half of the year. Despite a new partnership with Genentech and ongoing momentum for CASGEVY, second-quarter revenue declined 15% year-over-year, and the gross margin fell to 77%.
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall
MaxCyte reported Q2 2026 revenue of $7.3 million, exceeding analyst expectations, though shares fell after hours due to a year-over-year sales decline and lower margins. The company highlighted stabilization in the cell therapy market and a new enterprise partnership with Genentech as key developments. Despite short-term headwinds, MaxCyte remains confident in achieving low single-digit revenue growth in the second half of 2026 and expects more significant acceleration in 2027.
MaxCyte Reports Second Quarter 2026 Financial Results
MaxCyte, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $7.3 million, a 15% decrease year-over-year, and a net loss of $8.9 million, an improvement from the $12.4 million loss in Q2 2025. The company reiterated its full-year 2026 revenue guidance of $30 million to $32 million and highlighted a new multi-platform technology license partnership with Genentech. MaxCyte also noted the repurchase of approximately $5.5 million of common stock under its authorized $10 million share repurchase program.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this year. The company currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026.
MaxCyte, Inc. has provided an update on its equity buyback plan announced on May 12, 2026. As of August 12, 2026, the company has repurchased 4,730,105 shares, representing 4.42% of its stock, for a total of $5.5 million. This repurchase completes the program initiated earlier in the year.
MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph
This document is a statement of changes in beneficial ownership of securities for Director Johnston John Joseph at MaxCyte. These types of filings are routine disclosures required for company insiders. The specific details of the changes in ownership are contained within the document.
Latest MXCT ETF News Today | Earnings, Events & Price Alerts
This page provides the latest news and updates for MXCT ETF, including earnings reports, significant partnerships, and strategic developments. Recent headlines cover MaxCyte's collaborations with Genentech and Adicet Bio, Q4 2025 earnings results and forecasts for 2026 revenue, and executive appointments. The company has also undergone operational restructuring to reduce costs.
River Global Investors Discloses Investment at MaxCyte with 0.78% Stake
River Global Investors LLP has disclosed a 0.78% stake in MaxCyte, Inc. common stock as of July 31, 2026. This change in holdings follows a corporate restructuring at River Global Investors' parent company, with Liontrust Investment Partners LLP assuming responsibility for certain funds and most voting rights. River Global Investors will transfer its remaining 0.8% voting rights at a later stage.
MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake
River Global Investors LLP has reported a significant shift in its holding of MaxCyte, Inc. (MXCT) shares. Following the FCA's approval of a change in control and acquisition of River Global Holdings Limited, approximately 4.3% of MaxCyte voting rights transferred from River Global Investors to Liontrust Investment Partners LLP. River Global Investors now beneficially owns 834,100 shares, representing 0.7786% of MaxCyte's equity, with plans for the remaining 0.8% voting rights to transfer later.
Enterprise value to EBIT forward of MaxCyte, Inc. – NASDAQ:MXCT
This article from TradingView focuses on the enterprise value to EBIT forward for MaxCyte, Inc. (NASDAQ: MXCT). It appears to be a financial data page rather than a traditional article, providing a snapshot of a specific financial metric for the company.
BlackRock (MXCT holder) discloses 1,402,591 MaxCyte shares, a 1.3% ownership stake
BlackRock, Inc. has disclosed a 1.3% ownership stake in MaxCyte, Inc. common stock, amounting to 1,402,591 shares as of June 30, 2026. This information comes from an amended Schedule 13G/A SEC filing, indicating BlackRock holds sole voting and dispositive power over these shares. The filing clarifies that BlackRock's beneficial ownership is 5% or less of the class, with no single underlying client holding more than 5% interest in MaxCyte's outstanding common shares.
MXCT|MaxCyte Inc|Price:1.050|
MaxCyte Inc. is a cell-engineering company that provides solutions for cell therapeutics through its ExPERT platform, based on Flow Electroporation technology. The company's products include instruments, processing assemblies, and software protocols, supported by a worldwide intellectual property portfolio. MaxCyte also offers off-target risk assessment solutions for gene editing and has a market capitalization of $117.07 million with 292 institutions holding shares as of Q1 2026.
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for MaxCyte Inc (MXCT), highlighting its current risk score and beta value. The company's risk score is 2.63, ranking it 147 out of 199 in the Healthcare Equipment & Supplies industry. With a beta of 1.45, MXCT stock is shown to be more volatile than the S&P 500, performing better in uptrends but declining more in downtrends.
Enterprise value to EBIT forward of MaxCyte, Inc. – DUS:MYE0
This article provides financial information for MaxCyte, Inc. (DUS:MYE0) on the TradingView platform, specifically focusing on its enterprise value to EBIT forward. It indicates the market for this stock was closed with no trades recorded. The content is primarily a data presentation, noting the source and copyright of the financial and reference data used.
MXCT|MaxCyte Inc|Price:1.050|Chg%:+0.030
The article provides a comprehensive stock analysis of MaxCyte Inc (MXCT), highlighting its healthy fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes strong institutional ownership and a "Buy" rating from multiple analysts with a significant upside price target. Despite recent weak market performance, the company's stock is expected to trend upwards in the medium term, trading sideways between support and resistance levels.
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MaxCyte Inc (MXCT), detailing its current price momentum, support and resistance levels, and indicator readings. The stock is currently trading between $0.87 and $1.33, with a neutral overall signal based on moving averages and other technical indicators. The analysis includes specific values for MACD, RSI, KDJ, and various moving averages, along with explanations of these technical tools.
MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of MaxCyte Inc (MXCT), highlighting its current valuation score of 7.64 and its ranking within the Healthcare Equipment & Supplies industry. It notes the company's current P/E ratio is -2.78, which is significantly lower than its recent high and higher than its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
MaxCyte Inc (MXCT) Institutional Confidence
MaxCyte Inc (MXCT) currently holds an institutional shareholding score of 7.00, placing it 78th out of 199 companies in the Healthcare Equipment & Supplies industry. Institutional investors hold 74.61% of shares, a slight decrease of 0.07% over the last quarter. James Simons is the largest institutional shareholder, with a 1.86% stake in the company.
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates
MaxCyte Inc (MXCT) has an earnings forecast score of 8.29, ranking 53rd in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $5.72, with a majority recommending a "Buy" despite a recent EPS miss. The company's expected revenue for the next quarter is $6.48M.
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of MaxCyte Inc's (MXCT) dividend history and stock split events. It states that MaxCyte Inc has not distributed any dividends over the past five years. The page also displays current stock information such as price, market cap, and links to other financial data.
MaxCyte, Inc. Revenue Breakdown – DUS:MYE0
MaxCyte, Inc. generated €28.12 million in revenue last year, with its top-performing segment, PA Revenue, contributing €10.12 million. The majority of the company's revenue came from the United States, which accounted for €17.95 million.
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for MaxCyte Inc (MXCT) for the fiscal year 2024, updated on April 6. It categorizes revenue by business segments, showing that product sales account for 56.59% and licenses for 37.45%. Geographically, 63.82% of the revenue originates from inside the United States, with the remaining 36.18% from outside.
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4
Stifel has reiterated its Buy rating for MaxCyte (MXCT.US) and maintained its target price of $4. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and valuation.
MaxCyte stock surges on Genentech technology license deal By Investing.com
MaxCyte Inc. shares surged 5.6% following a technology license partnership announcement with Genentech, a Roche Group member. The deal grants Genentech access to MaxCyte’s ExPERT GTx platform to advance cell therapy programs from research to manufacturing. This collaboration aims to enhance cell engineering and gene editing capabilities across the cell therapy development lifecycle, though financial terms were not disclosed.
Brooklands Fund Management Ltd Invests $1.54 Million in MaxCyte, Inc. $MXCT
Brooklands Fund Management Ltd has invested approximately $1.54 million in MaxCyte, Inc. by acquiring 2.19 million shares, making it their 17th largest holding. MaxCyte, a cell therapy platform company, has also seen increased interest from other institutional investors, with 68.81% of its stock now owned by hedge funds and institutions. Despite recent positive EPS, the company missed revenue estimates, and analysts currently rate the stock as a "Hold" with a consensus price target of $5.00.
Genentech Gets Access to MaxCyte Cell-Engineering Platforms
MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to advance cell therapy programs. This agreement grants Genentech access to MaxCyte's ExPERT GTx platform and other technologies to support ex vivo cell engineering applications across research, clinical development, and manufacturing workflows. The collaboration aims to streamline the development of next-generation cell-based therapeutics by integrating complementary capabilities in cell engineering and gene editing.
MaxCyte Grants Roche Cell Therapy Tech License
MaxCyte has signed a multi-platform technology license agreement with Genentech, a member of the Roche Group, granting Genentech access to MaxCyte’s cell-engineering technologies for research, clinical development, and manufacturing across multiple internal programs. The agreement includes MaxCyte’s ExPERT GTx platform and other undisclosed technologies for ex vivo cell engineering, supporting Genentech's expansion in cell therapy. Financial terms and specific program details were not disclosed.
MaxCyte Grants Roche Cell Therapy Tech License
MaxCyte has granted Genentech, a member of the Roche Group, a multi-platform technology license for its cell-engineering technologies. This agreement provides Genentech with non-exclusive access to MaxCyte's ExPERT GTx platform and other technologies for use across multiple research, clinical development, and manufacturing programs. The financial terms and specific programs were not disclosed, but the deal strengthens Genentech's cell therapy manufacturing capabilities and expands MaxCyte's pharmaceutical customer base.
MaxCyte stock surges on Genentech technology license deal
MaxCyte Inc. shares rose 5.6% after announcing a technology license partnership with Genentech, a member of the Roche Group. The agreement grants Genentech access to MaxCyte’s ExPERT GTx platform and other technologies to support cell therapy program development across research, clinical development, and manufacturing. Financial terms of the deal were not disclosed.
Genentech licenses MaxCyte cell engineering technology By Investing.com
MaxCyte Inc. has announced a technology license partnership with Genentech, a member of the Roche Group, to support cell therapy program development. This agreement grants Genentech access to MaxCyte’s ExPERT GTx platform and other platform technologies, enabling support for ex vivo applications in cell engineering across research, clinical development, and manufacturing. The partnership aims to provide broad support throughout the cell therapy lifecycle by combining complementary capabilities in cell engineering and gene editing.
MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support
MaxCyte has announced a technology license partnership with Genentech, granting Genentech access to its ExPERT GTx® platform and other technologies. This multi-program license will support Genentech's cell therapy development across research, clinical development, and manufacturing. The collaboration aims to advance next-generation cell therapies by integrating cell engineering and gene editing to accelerate therapeutic development.
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MaxCyte, Inc. has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group, to advance cell therapy development. This agreement provides Genentech with access to MaxCyte's ExPERT GTx® platform and other technologies for research, clinical development, and manufacturing. The partnership aims to streamline cell therapy programs by integrating cell engineering and analytical workflows throughout the development lifecycle, supporting ex vivo applications for cell engineering.
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MaxCyte, Inc. announced a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. This agreement grants Genentech access to MaxCyte’s ExPERT GTx® platform and other platform technologies for research, clinical development, and manufacturing. The collaboration aims to streamline the advancement of cell therapy programs by integrating cell engineering and gene editing capabilities, ultimately accelerating the development of next-generation cell-based therapeutics.
MaxCyte (MXCT) Proxy filing Summary
This article summarizes MaxCyte's proxy filing from April 29, 2026, detailing voting matters and corporate governance. Key points include the election of three Class II directors and the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board recommends voting in favor of all nominees and the auditor ratification.
MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary
This summary details MaxCyte's (MXCT) presentation at the 44th Annual William Blair Growth Stock Conference. Key points include the evolving landscape of cell and gene therapy, MaxCyte's proprietary electroporation technology and platform capabilities, and its business model and financial performance, which features a razor-razorblade and licensing approach with significant clinical pipeline and positive Q1 2024 revenues. The company anticipates continued growth driven by new licenses and regulatory advancements in the cell and gene therapy sector.
